Medical applications of radiation Knowledge-Based Study

Study notes

1. Overview of Nuclear Medicine

   Nuclear medicine utilizes the unique properties of unstable atomic nuclei to diagnose and treat diseases. While conventional radiology (such as standard X-rays and computed tomography) relies on radiation transmitted through the body from an external machine, nuclear medicine typically administers radioactive substances known as radiopharmaceuticals directly into the patient.

   A radiopharmaceutical consists of two primary components:

   • A radionuclide (radioisotope): An unstable nucleus that decays by emitting detectable or cytocidal radiation (gamma rays, positrons, beta particles, or alpha particles).
   • A carrier molecule: A biologically active compound that specifically targets a particular organ, tissue type, or metabolic pathway in the human body.

   Medical radiation procedures are broadly classified into two categories: diagnostic techniques, which visualize physiological processes and organ anatomy, and therapeutic applications, which destroy targeted pathological cells, such as malignant tumors.

   The Tracer Principle

   Diagnostic imaging exploits the radioactive tracer principle, first pioneered by George de Hevesy. Because isotopes of an element exhibit virtually identical chemical behavior, the human body metabolizes a radiolabeled substance in the same manner as its stable counterpart. Consequently, minute, non-toxic amounts of radioisotopes can track physiological function without disrupting normal biochemical processes.

   Ideal Diagnostic Radionuclide Characteristics

   An optimal diagnostic radioisotope must satisfy specific physical criteria:

   • Gamma or Positron Emission: Emitted photons must possess sufficient energy (typically 100 to 250 keV) to penetrate tissue and exit the body without delivering excessive localized ionization damage to nearby healthy cells. Pure gamma emitters are preferred over alpha or beta emitters for imaging.
   • Short Physical Half-Life: The half-life must be long enough to synthesize the compound, administer it, and complete the scan, but short enough to minimize the cumulative radiation dose to the patient (usually on the order of hours).
   • Non-Toxic Daughter Nuclide: The decay product must be stable or have minimal radiotoxicity.

   Common Diagnostic Radioisotopes

   • Technetium-99m ($^{99\text{m}}\text{Tc}$): The most widely used medical radioisotope worldwide. It emits gamma rays of 140 keV with a physical half-life of approximately 6.0 hours, decaying to ground-state Technetium-99 via isomeric transition. It readily binds to various carrier ligands to image the skeleton, heart muscle, thyroid, and brain.
   • Fluorine-18 ($^{18}\text{F}$): A positron emitter ($\beta^+$) with a half-life of 110 minutes, extensively utilized in Positron Emission Tomography (PET). When bound to glucose, it forms fluorodeoxyglucose ($^{18}\text{F}\text{-FDG}$), which accumulates in metabolically hyperactive cells, notably cancer cells undergoing rapid glycolysis. Upon positron emission, the positron encounters an electron, resulting in an annihilation event that yields two collinear 511 keV gamma photons detected by the PET scanner.
   • Iodine-123 ($^{123}\text{I}$): A gamma emitter ($t_{1/2} = 13.2\text{ h}$) utilized to assess thyroid morphology and iodine uptake kinetics.

   Targeted Radiotherapy and Cell Destruction

   In contrast to diagnostic applications where tissue damage must be strictly minimized, therapeutic applications deliberately exploit ionizing radiation to induce double-strand DNA breaks in diseased cells, triggering apoptosis and preventing cellular proliferation.

   Therapy relies primarily on particulate radiation—namely beta minus ($\beta^-$) particles and alpha ($\alpha$) particles—which feature high linear energy transfer (LET) and relatively short penetration depths, depositing their destructive kinetic energy within a localized cellular radius.

   Internal Radiotherapy

   • Iodine-131 ($^{131}\text{I}$): A radionuclide that decays via beta-minus emission accompanied by gamma radiation ($t_{1/2} = 8.02\text{ days}$). Because the thyroid gland naturally concentrates iodide ions, oral administration of $^{131}\text{I}$ results in targeted ablation of hyperthyroid tissue or residual thyroid carcinoma cells, sparing distant organs.
   • Lutetium-177 ($^{177}\text{Lu}$): A beta emitter with a range of a few millimeters in tissue, frequently conjugated to peptides (e.g., in peptide receptor radionuclide therapy) to treat neuroendocrine tumors and metastatic prostate cancer.
   • Radium-223 ($^{223}\text{Ra}$): An alpha emitter that acts as a calcium mimetic, selectively targeting bone metastases in advanced prostate cancer and delivering high-LET radiation across a microscopic range of less than 100 micrometers.

   External Beam Radiation Therapy (EBRT) and Brachytherapy

   Medical radiation can also be applied externally or via sealed sources:

   • Teletherapy (External Beam): High-energy gamma radiation from sources such as Cobalt-60 ($^{60}\text{Co}$, $t_{1/2} = 5.27\text{ years}$), or high-energy X-rays produced by linear accelerators (LINACs), is focused from multiple angles onto a tumor mass, maximizing the dose to the malignancy while sparing intervening healthy tissue.
   • Brachytherapy: Small sealed radioactive "seeds" containing isotopes such as Iodine-125 ($^{125}\text{I}$) or Palladium-103 ($^{103}\text{Pd}$) are surgically implanted directly into or adjacent to the tumor (e.g., in localized prostate or cervical cancers), providing continuous, localized irradiation over time.

   Balancing Efficacy, Half-Life, and Patient Safety

   The application of nuclear chemistry in healthcare necessitates precise control over radiation dose to adhere to the fundamental radiation safety principle known as ALARA (As Low As Reasonably Achievable).

   Physical, Biological, and Effective Half-Life

   When evaluating radiation burden, clinicians distinguish between three interconnected decay parameters:

   • Physical Half-Life ($T_p$): The time required for half of the radioactive atoms to decay physically, governed strictly by nuclear instability.
   • Biological Half-Life ($T_b$): The time required for the body to eliminate half of the administered substance via natural physiological excretion pathways (such as renal clearance or exhalation).
   • Effective Half-Life ($T_e$): The actual rate of clearance combining both nuclear decay and biological excretion, calculated using the relationship:

   $$\frac{1}{T_e} = \frac{1}{T_p} + \frac{1}{T_b} \quad \implies \quad T_e = \frac{T_p \times T_b}{T_p + T_b}$$

   Because $T_e$ is always shorter than either $T_p$ or $T_b$ alone, selecting radiopharmaceuticals with suitable biological excretion profiles helps prevent long-term internal exposure.

   Core Protection Guidelines

   To protect both healthcare personnel and patients during medical nuclear procedures, three fundamental parameters are monitored:

   1. Time: Minimizing the duration of contact with radioactive sources directly reduces cumulative exposure.
   2. Distance: Maximizing distance from the emitter reduces radiation intensity according to the inverse-square law ($I \propto 1/d^2$).
   3. Shielding: Placing dense shielding materials (such as lead glass or lead aprons for gamma rays, and low-Z materials like acrylic for pure beta emitters to avoid Bremsstrahlung radiation) between the emitter and personnel attenuates radiation effectively.